Béa Fertility, a London, UK-based fertility tech startup making clinical-grade fertility care available at home, raised $3.2m in funding.
The round, which brought total funding to date to $4.2m, was led by Octopus Ventures and joined by JamJar and Forward Partners, with additional participation from existing investors Calm/Storm and Q Ventures.
The company intends to use the funds to release its first at-home fertility treatment to early adopters in the UK.
Led by femtech expert Tess Cosad and product engineer George Thomas, Béa Fertility has developed a clinical-grade at-home fertility kit that enables users to carry out a treatment called Intracervical Insemination (ICI) safely at home.
The Béa Treatment involves placing a small cervical cap containing semen at the cervix using a clinically-approved applicator. The cap is left in-situ for an hour; and during that time, users can go about their days as normal. Two weeks after treatment, users test for pregnancy. There are no invasive hormone injections or clinical procedures involved. The Béa Treatment is designed to be used at home and can be used with donor semen.
The first treatment is available to purchase online via Béa’s website now.
Béa Fertility is also launching a pioneering pilot which will trial the use of the Béa Treatment Kit within the NHS. Working in partnership with South Fulham Primary Care Network, the company will be providing direct access to fertility treatment in primary care.
FinSMEs
31/07/2023